Reimbursement of Digital Therapeutics in the U.S.

What Is the Outlook?

Home / Intelligence / White Papers / Reimbursement of Digital Therapeutics in the U.S.

Digital therapeutics (DTx) are impacting how patients are treated, interact with their providers and think about their own health. DTx have garnered interest from the investment community as well as pharma companies seeking an integrated digital offering. However, payers have not yet established a clear framework for integrating these technologies in their plans.

Coverage of DTx to date has been limited and the outlook for it is unclear. We spoke to four medical and pharmacy directors from large payer organizations in the U.S. to understand how the payer landscape for DTx might evolve in the future.

Download this white paper to understand:

  • The current requirements for DTx coverage in the U.S.
  • Perspectives from payers about the future of DTx coverage – including the feasibility and mechanics of a digital formulary in a future DTx market landscape
  • How Pear Therapeutics positioned itself as a leader in developing and commercializing prescription DTx (case study)
  • Key implications for DTx manufacturers, pharmaceutical manufacturers, providers and patients

Complete the form below to access the full white paper

By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email

Related Intelligence